Sign inJoin waitlistJoin the waitlist

Karim ElSahwi

Assistant Professor, Department of Obstetrics and Gynecology, Hackensack Meridian School of Medicine · Hackensack Meridian Health

Credentials: · · · · · ·

History

Hackensack Meridian Health
Present

Gynecologic Oncology
Yale Univ Sch of Med
2012–2015
Obstetrics and Gynecology
Jersey Shore University Medical Center
2008–2012
ALEXANDRIA UNIV, ALEXANDRIA
1990–1994

Research

Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor…
Journal of Clinical Oncology · 2018 · 400 citations
Randomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that…
Clinical Cancer Research · 2020 · 249 citations
In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma
British Journal of Cancer · 2010 · First of 16 authors · 96 citations

Alessandro Santin
13 papers
PS
Peter Schwartz
12 papers
Masoud Azodi
11 papers
Dan-Arin Silasi
9 papers · 7 as a fellow
Thomas Rutherford
9 papers
Natalia Buza
7 papers · 5 as a fellow
Elena Ratner
6 papers · 4 as a fellow
Noelle Aikman
5 papers
Verda Hicks
5 papers
FT
Fattaneh Tavassoli
4 papers
Pei Hui
4 papers
Ahmet Gurakar
3 papers

Clinical trials

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2022–2027